Abstract: This invention relates to compositions of matter, methods, modules and instruments for automated mammalian cell growth and mammalian cell transduction followed by nucleic acid-guided nuclease editing in live mammalian cells.
Type:
Application
Filed:
November 8, 2023
Publication date:
May 2, 2024
Applicant:
Inscripta, Inc.
Inventors:
Burak Dura, Phillip Belgrader, Christian Siltanen, William Watterson, Bruce Chabansky, David Stumbo, Eric Smith, Jorge Bernate
Abstract: The present disclosure provides engineered nucleic acid-guided nickases and optimized scaffolds for making rational, direct edits to nucleic acids in live cells.
Abstract: The present disclosure provides modules, instruments and methods to enrich for cells edited via nucleic acid-guided nuclease editing of live cells.
Type:
Grant
Filed:
August 20, 2019
Date of Patent:
April 23, 2024
Assignee:
Inscripta, Inc.
Inventors:
Eileen Spindler, Isaac Wagner, Clint Davis, Julia Swavola, Phillip Belgrader
Abstract: The present disclosure relates to synthetic biology and, in particular, the expression of heterologous proteins in a microbial cell, and engineered enzymes for achieving the same.
Abstract: The present disclosure provides compositions of matter, methods, systems, and instruments for improved nucleic acid-guided nuclease editing in live cells, wherein the live cells are shifted into a growth-arrested state for editing.
Type:
Application
Filed:
August 31, 2023
Publication date:
March 7, 2024
Applicant:
Inscripta, Inc.
Inventors:
Karl GERHARDT, Charles JOHNSON, Martha BRAUN
Abstract: The present disclosure relates to methods and compositions of matter to increase the percentage of edited cells in a cell population when employing nucleic-acid guided editing methods, as well as systems and instruments for performing these methods and using these compositions.
Type:
Application
Filed:
July 26, 2023
Publication date:
February 15, 2024
Applicant:
Inscripta, Inc.
Inventors:
Jacob BRAMMER, Jeffrey QUINN, Erik ZIMMERMAN
Abstract: The present disclosure provides compositions of matter, methods and instruments for nucleic acid-guided nickase/reverse transcriptase fusion enzyme editing of nucleic acids in live mammalian cells.
Abstract: The present disclosure relates to methods for increasing observed editing rates in the surviving bacteria cells. The compositions and methods presented herein in combination lead to a phenomenon of “edit or die.” Although less cells survive plating and editing, a large percentage of cells that do survive are multiple editors. In one experiment it was found that if a cell survives transformation, plating, and editing, 75% of the surviving cells are multiple editors; that is, 75% of the surviving cells were simultaneously edited with edits at two or more different locations within the bacterial genome.
Type:
Grant
Filed:
February 25, 2022
Date of Patent:
February 6, 2024
Assignee:
Inscripta, Inc.
Inventors:
Tian Tian, Eileen Spindler, Charles Johnson, Clint Davis
Abstract: The present disclosure provides compositions of matter, methods and instruments for nucleic acid-guided nickase/reverse transcriptase fusion enzyme editing of nucleic acids in live mammalian cells.
Abstract: The present disclosure provides compositions of matter, methods and instruments for nucleic acid-guided nickase/reverse transcriptase fusion editing in live cells. Editing efficiency is improved using fusion proteins (e.g., the nickase-RT fusion) that retain certain characteristics of nucleic acid-directed nucleases (e.g., the binding specificity and ability to cleave one or more DNA strands in a targeted manner) combined with reverse transcriptase activity. Editing cassettes are employed, comprising a gRNA and a repair template where the 3? end of the repair template is protected from degradation.
Abstract: Nucleic acid-guided nuclease editing in mammalian cells may include passaging mammalian cells, in an automated closed cell editing instrument, into smaller aggregates when the aggregates exceed 50-300 microns in size. A library of viral particles may be delivered to the mammalian cells at a multiplicity of infection such that each mammalian cell receives one or no viral particle. The library may include viral vectors with an editing cassette including a pair of gRNA coding sequence and donor DNA. Conditions may be provided to allow a viral vector of the viral vectors to integrate into the mammalian cells. Enriching for mammalian cells may be done with an integrated viral vector. A nucleic acid-guided nuclease or nuclease fusion or a coding sequence for a nucleic acid-guided nuclease or nuclease fusion may be delivered to the enriched mammalian cells and conditions may be provided to allow editing in the mammalian cells.
Type:
Grant
Filed:
May 31, 2022
Date of Patent:
December 19, 2023
Assignee:
INSCRIPTA, INC.
Inventors:
Burak Dura, Phillip Belgrader, Christian Siltanen, William Watterson, Bruce Chabansky, David Stumbo, Eric Smith, Jorge Bernate
Abstract: The present disclosure relates to synthetic biology and, in particular, the bioproduction of bakuchiol, and engineered enzymes for producing the same.
Abstract: The present disclosure relates to various different types of mutations in the thrA gene in E. coli leading to enhanced lysine production for, e.g., supplements and nutraceuticals.
Type:
Grant
Filed:
May 12, 2021
Date of Patent:
October 17, 2023
Assignee:
Inscripta, Inc.
Inventors:
Eric Abbate, Katherine Krouse, Richard Fox, Daniel Held, Michael Clay, Nandini Krishnamurthy
Abstract: The present disclosure provides automated multi-module instrumentation and automated methods for performing recursive editing of live cells with curing of editing vectors from prior rounds of editing.
Type:
Application
Filed:
March 13, 2023
Publication date:
September 21, 2023
Applicant:
Inscripta, Inc.
Inventors:
Charles Johnson, Tian TIAN, Eileen SPINDLER
Abstract: The present disclosure provides instruments, modules and methods for improved detection of edited cells following nucleic acid-guided nuclease genome editing. The disclosure provides improved automated instruments that perform methods—including high throughput methods—for screening cells that have been subjected to editing and identifying cells that have been properly edited.
Type:
Grant
Filed:
December 17, 2021
Date of Patent:
August 29, 2023
Assignee:
INSCRIPTA, INC
Inventors:
Andrew Garst, Richard Fox, Phillip Belgrader, Don Masquelier
Abstract: The present disclosure relates to compositions, methods, modules and automated integrated instrumentation for multiplex delivery of “landing pad” edits into the genomes of a population of live cells. The landing pads then may be leveraged to insert very large DNA sequences into the genomes of the population of live cells.
Abstract: Compositions of matter, methods, modules, and automated instruments may relate to synthesizing a library including an editing cassette including a different gRNA and donor DNA pair, amplifying the editing cassette in a partition separate from other editing cassettes in the library, adding nuclease to the partition, and adding lipofectamine to the editing cassette and nuclease to form a lipofectamine/nucleic acid/nuclease complex. A microcarrier coated in extracellular matrix or a cell adhesion molecule coating may be added to the lipofectamine/nucleic acid/nuclease complex. Cell growth material, the microcarrier, and mammalian cells may be transferred to a growth module in an automated closed cell editing instrument via a liquid handling system. The mammalian cells may be allowed to seed on the microcarrier. Conditions may be provided for the mammalian cells to take-up and be edited by a payload associated with the lipofectamine/nucleic acid/nuclease complex.
Type:
Application
Filed:
February 24, 2023
Publication date:
August 10, 2023
Applicant:
Inscripta, Inc.
Inventors:
Phillip Belgrader, Nathan Bade, Christian Siltanen, Aamir Mir, Xi-Jun Chen, Janine Mok, Burak Dura, Bruce Chabansky, David Stumbo, Eric Smith, Jorge Bernate
Abstract: The present disclosure provides shuttle vectors for editing exogenous polynucleotides in heterologous live cells, as well as automated methods, modules, and multi-module cell editing instruments and systems for performing the editing methods.
Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
Type:
Grant
Filed:
May 24, 2019
Date of Patent:
July 11, 2023
Assignee:
Inscripta, Inc.
Inventors:
Ryan T. Gill, Andrew Garst, Tanya Elizabeth Warnecke Lipscomb